A newly published interview in the American Journal of Managed Care features Andrew Alexis, MD, MPH, discussing how new therapies are shifting the landscape for skin of color dermatology.

Alexis, a leading clinician-researcher in the field, addressed the topic in the outlet's interview format. The conversation centers on how expanding therapeutic options are changing management approaches for patients with skin of color.

The interview's framing — that new therapies are "shifting the landscape" — signals a period of rapid change in a subspecialty area that has historically been underrepresented in clinical research and trial populations.

Why this matters for dermatology readers

Skin of color dermatology has long faced a evidence gap: darker skin phototypes have been underenrolled in pivotal trials across inflammatory dermatoses, and pigmentary considerations — post-inflammatory hyperpigmentation, keloid scarring, and differences in disease presentation — complicate both diagnosis and treatment selection.

An interview with Alexis on this topic carries weight because of his role in building the evidence base for treating common conditions in patients with Fitzpatrick skin types IV through VI, including acne, rosacea, seborrheic dermatitis, melasma, and psoriasis. When a clinician of his standing characterizes the current moment as a shift, readers can expect discussion of specific agents and device-based options rather than general commentary.

What readers should watch for

The American Journal of Managed Care typically publishes such interviews in conjunction with coverage of major dermatology meetings or in connection with managed-care and access themes. Given the outlet's focus, the conversation may address not only clinical efficacy but also coverage, reimbursement, and the practical availability of newer agents for diverse patient populations.

A note on sourcing

The headline and attribution confirming the interview's existence and its central claim — that new therapies are shifting the landscape for skin of color dermatology — come directly from the American Journal of Managed Care. The full text of the interview, including the specific therapies Alexis names, the conditions he discusses, and any trial data he cites, sits behind the publication's original article, which Derm Field readers can consult for the complete conversation.

Until that full text is reviewed, Derm Field advises treating this item as a coverage alert rather than a clinical summary. No specific drug names, endpoints, study designs, or patient populations can be attributed to the interview on the basis of the headline alone.

The road ahead

As the interview circulates, expect skin-of-color treatment conversations at upcoming dermatology meetings to build on the themes Alexis raises, with trial diversity mandates and newer systemic agents likely anchoring the discussion.